Charlie Barker
@charliegbarker.bsky.social
Postdoc at BioMed X with Team VPE | PhD at @emblebi |
Interested in modeling cell signaling in the contexts of disease and dysregulation
Interested in modeling cell signaling in the contexts of disease and dysregulation
Reposted by Charlie Barker
@georgegalea.bsky.social, @kuodyte.bsky.social, Pepperkok et al. reveal that RAD51C is anchored at the #Golgi by Giantin until DNA damage triggers ATM-dependent release & nuclear import, establishing the Golgi as a spatiotemporal regulator of nuclear #DNArepair rupress.org/jcb/article/...
July 28, 2026 at 4:01 PM
@georgegalea.bsky.social, @kuodyte.bsky.social, Pepperkok et al. reveal that RAD51C is anchored at the #Golgi by Giantin until DNA damage triggers ATM-dependent release & nuclear import, establishing the Golgi as a spatiotemporal regulator of nuclear #DNArepair rupress.org/jcb/article/...
Reposted by Charlie Barker
Out now in Nature Metabolism! 🖥️🧬
An Open Targets project has identified a set of plasma proteins that could be used to diagnose and monitor patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
www.nature.com/articles/s42...
An Open Targets project has identified a set of plasma proteins that could be used to diagnose and monitor patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
www.nature.com/articles/s42...
A data-driven framework reconstructs the molecular continuum of human MASLD progression - Nature Metabolism
A trajectory-based molecular framework reveals coordinated temporal shifts in metabolic, inflammatory and fibrogenic mechanisms across the human MASLD spectrum.
www.nature.com
July 14, 2026 at 9:17 AM
Out now in Nature Metabolism! 🖥️🧬
An Open Targets project has identified a set of plasma proteins that could be used to diagnose and monitor patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
www.nature.com/articles/s42...
An Open Targets project has identified a set of plasma proteins that could be used to diagnose and monitor patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
www.nature.com/articles/s42...
Reposted by Charlie Barker
Congratulations to Fisher Lab @ucl.ac.uk on predicting combinations of anticancer drugs, was privileged to be part of the consortium. Executable models offer insights that black box models do not. pubmed.ncbi.nlm.nih.gov/42341181/ @icr.ac.uk @crukconvergence.bsky.social
July 6, 2026 at 11:45 AM
Congratulations to Fisher Lab @ucl.ac.uk on predicting combinations of anticancer drugs, was privileged to be part of the consortium. Executable models offer insights that black box models do not. pubmed.ncbi.nlm.nih.gov/42341181/ @icr.ac.uk @crukconvergence.bsky.social
Reposted by Charlie Barker
Our preprint is published in MSB! This time with the correct preprint post below! link.springer.com/article/10.1...
March 3, 2026 at 11:39 AM
Our preprint is published in MSB! This time with the correct preprint post below! link.springer.com/article/10.1...
Reposted by Charlie Barker
📢 Recruitment for the EMBL International PhD Programme is officially open!
At EMBL, we train young scientists to become skilled and creative future leaders in academia and other sectors. Join us and get a head start on your career in life sciences!
bit.ly/47mmiFF
At EMBL, we train young scientists to become skilled and creative future leaders in academia and other sectors. Join us and get a head start on your career in life sciences!
bit.ly/47mmiFF
September 1, 2025 at 9:07 AM
📢 Recruitment for the EMBL International PhD Programme is officially open!
At EMBL, we train young scientists to become skilled and creative future leaders in academia and other sectors. Join us and get a head start on your career in life sciences!
bit.ly/47mmiFF
At EMBL, we train young scientists to become skilled and creative future leaders in academia and other sectors. Join us and get a head start on your career in life sciences!
bit.ly/47mmiFF
Reposted by Charlie Barker
Excited to share our new preprint showcasing a method to infer transparent, mechanistic network models of biological pathways using graph neural networks! www.biorxiv.org/content/10.1...
May 26, 2025 at 9:50 PM
Excited to share our new preprint showcasing a method to infer transparent, mechanistic network models of biological pathways using graph neural networks! www.biorxiv.org/content/10.1...
Reposted by Charlie Barker
Crick researchers have found that certain aggressive lung cancer cells can develop their own electric network, similar to the body’s nervous system.
This can allow tumour cells to go ‘off grid,’ making them harder to treat.
www.crick.ac.uk/news/2025-02...
This can allow tumour cells to go ‘off grid,’ making them harder to treat.
www.crick.ac.uk/news/2025-02...
Lung cancer cells can go ‘off grid’
Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body’s nervous system. This un...
www.crick.ac.uk
February 12, 2025 at 4:35 PM
Crick researchers have found that certain aggressive lung cancer cells can develop their own electric network, similar to the body’s nervous system.
This can allow tumour cells to go ‘off grid,’ making them harder to treat.
www.crick.ac.uk/news/2025-02...
This can allow tumour cells to go ‘off grid,’ making them harder to treat.
www.crick.ac.uk/news/2025-02...
Reposted by Charlie Barker
We then used our published method from @charliegbarker.bsky.social (Barker et al, Genome Research, 2022) to create a reference MASLD network by associating gene co-expression modules with histology scores, identifying key transcription factors regulating them and applying network reconstruction.
January 19, 2025 at 11:18 AM
We then used our published method from @charliegbarker.bsky.social (Barker et al, Genome Research, 2022) to create a reference MASLD network by associating gene co-expression modules with histology scores, identifying key transcription factors regulating them and applying network reconstruction.
🚨 New preprint!🚨 Tackling non-small cell lung cancer (NSCLC) adenocarcinoma with in silico models:
🌟 Models tumor pathways (EGFR, AKT, JAK/STAT, WNT)
🌟 personalized drug & radiotherapy combos
🌟 Identifies a signature for patient stratification
🌟 Models tumor pathways (EGFR, AKT, JAK/STAT, WNT)
🌟 personalized drug & radiotherapy combos
🌟 Identifies a signature for patient stratification
January 13, 2025 at 11:04 AM
🚨 New preprint!🚨 Tackling non-small cell lung cancer (NSCLC) adenocarcinoma with in silico models:
🌟 Models tumor pathways (EGFR, AKT, JAK/STAT, WNT)
🌟 personalized drug & radiotherapy combos
🌟 Identifies a signature for patient stratification
🌟 Models tumor pathways (EGFR, AKT, JAK/STAT, WNT)
🌟 personalized drug & radiotherapy combos
🌟 Identifies a signature for patient stratification
I got a bsky so that i could repost this!! Full publication to follow shortly but, would appreciate your feedback on the methods and results! 🔭🧪
We are proud to present "ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma" led by Charlie Barker and Sumana Sharma in collaboration with EPIC-XS Utrecht, ProtAvio, @sangerinstitute.bsky.social and UofAthens www.biorxiv.org/content/10.1...
ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma
Resistance to BRAF and MAPK inhibitors is a significant challenge in melanoma treatment, driven by adaptive and acquired mechanisms that allow tumour cells to evade therapy. Here, we examined early si...
www.biorxiv.org
December 10, 2024 at 2:04 PM
I got a bsky so that i could repost this!! Full publication to follow shortly but, would appreciate your feedback on the methods and results! 🔭🧪